Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers

Background: Over the past few years, significant advancements have been achieved in the front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will eventually encounter disease progression during this front-line treatment and require further therapeutic options. Whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Parosanu, Andreea Ioana, Baston, Catalin, Stanciu, Ioana Miruna, Parlog, Cristina Florina, Nitipir, Cornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378702/
https://www.ncbi.nlm.nih.gov/pubmed/37510173
http://dx.doi.org/10.3390/diagnostics13142430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378702/
https://www.ncbi.nlm.nih.gov/pubmed/37510173
http://dx.doi.org/10.3390/diagnostics13142430

Ejemplares similares